TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02619500

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: A standardized home exercise program will be given to subjects that will include active range of motion of the cervical and thoracic spine and deep cervical flexion endurance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: A standardized home exercise program will be given to subjects that will include active range of motion of the cervical and thoracic spine and deep cervical flexion endurance exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient advice, encouragement, and education
Description: Therapists will provide each subject with advice and education pertaining to their condition as well as encouragement towards reducing pain and disability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient advice, encouragement, and education
Description: Therapists will provide each subject with advice and education pertaining to their condition as well as encouragement towards reducing pain and disability.
Study: NCT01131013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.
Study: NCT02619500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation
Description: High velocity low amplitude (HVLA) thrust performed at or near the end range of a targeted segment in both the cervical and thoracic spine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-thrust Mobilizations
Description: Repetitive and rhythmic accessory passive movements applied with either small or large amplitude at a targeted segment to both the cervical and thoracic spine
Study: NCT02870231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-0530
Description: Once-daily subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NNC9204-0530
Description: Once-daily subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration
Study: NCT00469612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroVision's NVC treatment for Low Myopia
Description: NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain).~The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress.
Study: NCT04580290

Intervention type: DEVICE
Intervention: JewelACL
Description: The JewelACL is a polyester scaffold for anterior cruciate ligament (ACL) reconstruction

Intervention type: DEVICE
Intervention: JewelACL
Description: The JewelACL is a polyester scaffold for anterior cruciate ligament (ACL) reconstruction
Study: NCT02697383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib (MLN9708)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03073135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodrama Group Therapy (PGT)
Description: The psychotherapeutic focus is on the here and now aspect of the patient's relationships. Conflicts are acted out during the sessions, yielding intense emotional re-experience in a safe environment, which will bring further cognitive understanding of past distressful life experiences and hopefully new adaptive ways of expressing and dealing with the problem.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Group Therapy (SGT)
Description: SGT is a form of treatment in which the therapist maintains a therapeutic relationship and a working alliance based on reality, support, clarification, assistance in troubleshooting, strong leadership, partial gratification of dependency needs, legitimating independence, development of pleasurable activities and adequate rest, guidance and advice to deal with current problems. This approach uses techniques to help patients feel safe, accepted, protected, encouraged and not anxious.
Study: NCT02258880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN13837
Study: NCT01131013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.
Study: NCT02258880

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03206281

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal wight estimation
Description: We will estimate the fetal weight by sonographic and clinical estimation

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal wight estimation
Description: We will estimate the fetal weight by sonographic and clinical estimation
Study: NCT02458937

Intervention type: OTHER
Intervention: Functional Mobility Assessment
Description: Functional Mobility Assessment (FMA) is a tool that was developed to measure functional mobility in children and adolescents with lower-extremity sarcoma. It is comprised of well-established outcome measures that examine various domains of function. The six categories tested by the FMA include pain, functional mobility, use of assistive devices, satisfaction with quality of gait, participation in the community, and endurance.
Study: NCT02093442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial injury
Description: Endometrial biopsy using a pipelle de Cornier
Study: NCT02458937

Intervention type: OTHER
Intervention: GAITRite® System
Description: Subjects will be required to walk at a self-selected comfortable pace and again at fast speed. Software will then calculate and report the temporo-spatial gait parameters for collection and evaluation by the primary investigator.
Study: NCT03012074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes Self-Management
Description: Patients with Type 2 Diabetes
Study: NCT03446885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate 40 MG
Description: Lisdexamfetamine Dimesylate 40 MG administered orally
Study: NCT02458937

Intervention type: OTHER
Intervention: Range of Motion
Description: Measurements will include hip flexion, hip abduction and adduction, and hip internal and external rotation. Range of motion (ROM) will be attempted on bilateral lower extremities, however if post-operative ROM precautions are implemented, the involved extremity will not be measured. Goniometry is a reliable and valid measure for active and passive ROM when following standardized procedures.
Study: NCT04494100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRONC
Description: injection of 3 to 7 mL of Ropivacaine 3.75 mg/ml per nerve (median and ulnar nerves) and infiltration of 2 ml of Ropivacaine 3.75 mg/ml laterally above the flexion fold of the wrist in order to block the branches of the lateral cutaneous nerve of the forearm, the terminal sensory branch of the musculocutaneous nerve.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRONC
Description: injection of 3 to 7 mL of Ropivacaine 3.75 mg/ml per nerve (median and ulnar nerves) and infiltration of 2 ml of Ropivacaine 3.75 mg/ml laterally above the flexion fold of the wrist in order to block the branches of the lateral cutaneous nerve of the forearm, the terminal sensory branch of the musculocutaneous nerve.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WALANT
Description: infiltration with 3 to 7 ml of 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine and 8.4% sodium bicarbonate in the subcutaneous area in front of the transverse ligament, between the thenar and hypothenar eminences, from the flexion fold of the wrist over a length of 5 cm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: inflation pressure 75 to 100 mmHg above systolic blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: troncular blocks with Ropivacaine 3.75 mg/ml
Study: NCT03446885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate 40 MG
Description: Lisdexamfetamine Dimesylate 40 MG administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule administered orally
Study: NCT03412409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
Study: NCT02829021

Intervention type: DEVICE
Group type: OTHER
Intervention: FLIR ThermaCAM P-65
Description: Women recalled for assessment after positive screening mammography were offered dynamic infrared thermography before clinical mammography and further tests.
Study: NCT02571010

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Medical treatment
Description: Standard treatment with drugs and usual rehabilitation

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Medical treatment
Description: Standard treatment with drugs and usual rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical treatment
Description: Standard treatment with drugs and usual rehabilitation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation
Description: Rehabilitation by vibrotactile stimulation at medical center

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation with Vibradol device switched off
Description: Sham Rehabilitation at medical center but with Vibradol device switched off
Study: NCT05461079

Intervention type: DIAGNOSTIC_TEST
Intervention: obtention of up to three semen samples
Description: sorting of spermatozoa with flow cytometry. In the presence of insufficient numbers of spermatozoa after sorting (\<15 mill), up to three semen samples will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: obtention of up to three semen samples
Description: sorting of spermatozoa with flow cytometry. In the presence of insufficient numbers of spermatozoa after sorting (\<15 mill), up to three semen samples will be collected.
Study: NCT02480933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral mastectomy
Description: Bilateral mastectomy and imaging study of cadaveric breasts

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral mastectomy
Description: Bilateral mastectomy and imaging study of cadaveric breasts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy of BI-RADS 3 and superior lesions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy of BI-RADS 3 and superior lesions
Study: NCT04688294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: 30 patients initially received Sacubitril/Valsartan at 24/26 mg twice daily orally then dose was doubled as tolerated every 2-4 weeks to reach the target maintenance dose 97 mg/103 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 30 patients received valsartan, starting at a dose of 40 mg/day orally. The dose was then doubled every 1-2 weeks on the basis of their blood pressure to reach a dose of 160 mg once daily according to guideline-directed medical therapy.
Study: NCT00374803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid (Myfortic)
Description: * Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter~* Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid (Myfortic)
Description: * Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter~* Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day).
Study: NCT02529579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iAPA-DC/CTL adoptive cellular immunotherapy
Description: twice DC cell infusion and CTL cell infusion for 6 times

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: standard Gemcitabine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: standard Gemcitabine therapy
Study: NCT01448395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]NXL104
Description: 500mg/100mL intravenous solution
Study: NCT02290314

Intervention type: PROCEDURE
Group type: OTHER
Intervention: minimally invasive MID-line Lumbar Fusion (MIDLF)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Posterior lumbar interbody fusion (PLIF)
Study: NCT03685773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: MRI studies: Non-diabetic and T2D participants will receive diazoxide (up to 7 mg/kg) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive diazoxide (up to 7 mg/kg) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the pancreatic clamp study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: MRI studies: Non-diabetic and T2D participants will receive diazoxide (up to 7 mg/kg) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive diazoxide (up to 7 mg/kg) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the pancreatic clamp study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: MRI studies: Non-diabetic and T2D participants will receive diazoxide (up to 7 mg/kg) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive diazoxide (up to 7 mg/kg) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the pancreatic clamp study.
Study: NCT04494100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: troncular blocks with Ropivacaine 3.75 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine + Epinephrine
Description: WALANT technique with 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine
Study: NCT03685773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: MRI studies: Non-diabetic and T2D participants will receive diazoxide (up to 7 mg/kg) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive diazoxide (up to 7 mg/kg) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the pancreatic clamp study.
Study: NCT00154089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EM-1421
Description: EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
Study: NCT04586387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS) with sham and then active stimulation over bicep muscle
Description: repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS) with sham and then active stimulation over bicep muscle
Description: repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS) with sham and then active stimulation over finger muscle
Description: repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
Study: NCT04586387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS) with sham and then active stimulation over finger muscle
Description: repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
Study: NCT03685773

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for diazoxide)
Description: MRI studies: Non-diabetic and T2D participants will receive placebo (for diazoxide) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive a taste-matched placebo (for diazoxide) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive a taste-matched placebo (for diazoxide) the next morning and undergo the pancreatic clamp study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Description: Type 2 diabetic participants in this arm will receive a nicotinic acid infusion to lower free fatty acid levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the MRI or pancreatic clamp study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Description: Type 2 diabetic participants in this arm will receive a nicotinic acid infusion to lower free fatty acid levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the MRI or pancreatic clamp study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Description: Type 2 diabetic participants in this arm will receive a nicotinic acid infusion to lower free fatty acid levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the MRI or pancreatic clamp study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Description: Type 2 diabetic participants in this arm will receive a nicotinic acid infusion to lower free fatty acid levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the MRI or pancreatic clamp study.
Study: NCT02498873

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linear Periodization
Description: Linear Intensity Periodization Running

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non Linear Periodization
Description: Non Linear Periodization Running
Study: NCT04635306

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Approved GEBT test meal
Description: FDA-approve GEBT test meal
Study: NCT03248726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol and bisacodyl
Description: Intervention: Take 3 tablets (15mg) of stimulant laxatives Dulcolax® (bisacodyl) at 10pm the day before examination. Take two pack of osmotic laxative Klean-prep® powder (Polyethylene glycol) mixed with 2000ml water at 5am on the morning of examination.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Split-dose polyethylene glycol
Description: Take two pack of Klean-prep® powder mixed with 2000ml water at 6pm before the day of examination, and take another two pack of osmotic laxative Klean-prep® powder mixed with 2000ml water at 5am on the examination day.
Study: NCT04184817

Intervention type: OTHER
Intervention: Collection of clinical data registered in Easily software
Description: Collection of clinical data registered in Easily software
Study: NCT00887861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational new drug, company code: BGG492

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02505282

Intervention type: OTHER
Intervention: Vitamin K status
Description: Vitamin K status indicated by desphospho-uncarboxylated matrix Gla protein level

Intervention type: OTHER
Intervention: Vitamin K status
Description: Vitamin K status indicated by desphospho-uncarboxylated matrix Gla protein level
Study: NCT01180933

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: 400 mg of DHA and 150 mg of eicosapentaenoic acid per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folate
Description: 400 µg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil + folate
Description: 500 mg DHA, 150 mg eicosapentaenoic acid, 400 µg MTHF per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: only vitamins and minerals as recommended, but no fish oil or folate
Study: NCT01884831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions